Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
Key claim: The FIERCE trial will test whether a 16-week supervised clinic-based circuit program (resistance and functional exercises plus self-directed aerobic exercise) improves frailty, sarcopenia, and disease-progression outcomes in pre-frail/frail metastatic prostate cancer patients on androgen deprivation therapy.
Abstract
The purpose of this study is to determine whether a 16-week supervised, clinic-based circuit training intervention utilizing resistance and functional exercises and self-directed aerobic exercise will improve frailty and sarcopenic status and disease progression outcomes among pre-frail/frail metastatic prostate cancer patients receiving androgen deprivation therapy (ADT).
The names of the study intervention involved in this study is:
• Supervised circuit training (aerobic and resistance exercise regimen)
Why this matters
Androgen deprivation therapy for metastatic prostate cancer accelerates the sarcopenia–frailty trajectory that exercise research otherwise studies in general older adults, and FIERCE is one of the first trials to test a full multicomponent (resistance + functional + aerobic) program specifically in patients already pre-frail or frail on ADT. As a protocol, it does not yet resolve whether exercise modifies disease progression in this setting, but it will contribute a targeted readout on whether the strongest human-evidenced longevity lever transfers into a high-need oncology-aging niche.